Seroepidemiology of schistosomiasis japonica by ELISA in the Philippines. III. Selective mass chemotherapy with praziquantel in a control program.
After a pre-control (pre-treatment) prevalence rate of schistosomiasis japonica was established by stool examination and by ELISA in about 400 school children in school year 1979, annual prevalence rates were measured in the following 3 assessment years. From 54-80% of children found infected primarily by stool examination were treated with praziquantel 3-9 months before the assessment examinations. Both stool examination and ELISA showed statistically significant reductions of prevalence from the 1st to the 3rd assessment years (average reduction of 50% measured by stool examination and average reduction of 19% measured by ELISA). These reductions were expected as a result of the biologic activity of the effective schistosomicide; they are therefore not acceptable evidence of reduced transmission levels. By decreasing human sources of snail infection, an effective schistosomicide may have the epidemiologic impact of reducing transmission; assessment prevalence rates can be relevant indices of transmission levels only if the biologic effect of the schistosomicide is dissociated from its epidemiologic impact in a control program in which selective mass chemotherapy plays a dominant role. This dissociation was accomplished in this study by measurements in an essentially untreated group of "new" pupils, i.e., those who entered the school at the beginning of each assessment year. Overall prevalence rates among the "new" pupils did not show a significant reduction until the 3rd assessment year as measured by stool examination (reduction by 36% of pre-control level); as measured by ELISA, a significant reduction (by 15-17%) was detected in the 2nd and 3rd assessment years. The youngest children, and girls more than boys, were the most sensitive indicators of change.(ABSTRACT TRUNCATED AT 250 WORDS)
D000906:Antibodies / Q000032:analysis; D002648:Child; D005243:Feces / Q000469:parasitology; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D010679:Philippines; D011223:Praziquantel / Q000627:therapeutic use*; D012549:Schistosoma japonicum / Q000276:immunology; D012552:Schistosomiasis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control
D000906:Antibodies; D007546:Isoquinolines; D011223:Praziquantel